Adding abiraterone to the standard treatment for locally advanced prostate cancer, where the cancer has a high chance of spreading*, could halve the risk of death from the disease.

Giving the drug abiraterone alongside standard hormone therapy helps men with high-risk prostate cancer, that has not spread elsewhere in the body, live longer.

The Institute of Cancer Research, London, is disappointed at the decision by NICE not to recommend abiraterone as a first-line NHS treatment for newly diagnosed, advanced prostate cancer.